Inspiremd Inc (NSPR) 2.11 $NSPR
InspireMD Announces Positive Results from CGuard(TM) CARENET Trial with 0% MACE reported at 30 Days
PR Newswire - Tue Sep 16, 3:10PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced positive results from the CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard(TM) EPS. This trial demonstrates that the MicroNet(TM) covered CGuard may offer important clinical benefits for patients undergoing carotid artery stenting (CAS).
InspireMD to Present at the Aegis Healthcare and Technology Conference
PR Newswire - Wed Sep 03, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced that its Chief Financial Officer, Craig Shore, will be presenting at the Aegis Healthcare and Technology Conference at the Encore at Wynn Las Vegas. The Company will present on Friday, September 12, 2014 at 8:30 a.m. PT.
InspireMD to Announce Results of CGuard(TM) CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies
PR Newswire - Mon Aug 11, 7:00AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced that Professor Joachim Schofer, MD, at the Hamburg University Cardiovascular Center, will present the results of the CARENET (CARotid Embolic protection using microNET) trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference, in Washington, D.C. on Tuesday September 16, 2014.
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014
PR Newswire - Wed Jul 23, 3:05PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced its financial and operating results for the second quarter, which ended June 30, 2014.
InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2014 on Wednesday, July 23rd
PR Newswire - Thu Jul 17, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2014 on Wednesday, July 23rd.
InspireMD Appoints Dr. James Barry as Chief Operating Officer
PR Newswire - Tue Jul 15, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems, today announced the appointment of James Barry, Ph.D. as Chief Operating Officer. Barry, who has more than two decades of experience in the medical device industry, will be based in the Company's Boston headquarters.
InspireMD Announces Successful Completion of CGuard(TM) CARENET (CARotid Embolic protection study using microNET) Trial
PR Newswire - Tue Jul 08, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced that it has concluded enrollment in its CARENET clinical trial. The multi-specialty (Interventional Cardiologists, Interventional Radiologists and Vascular Surgeons) trial is assessing the peri-procedural safety and efficacy of CGuard systems in the treatment of carotid lesions. The acute procedural performance of the CGuard device was 100% successful for all of the 30 patients enrolled in the trial.
InspireMD Selected for Inclusion in the Russell Microcap® Index
PR Newswire - Tue Jul 01, 7:30AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems, today announced that it has been selected to join the Russell Microcap Index, as of June 27, 2014.
Global Coronary Stent Market through 2019 - Concise Analysis of the Projected $13 Billion Industry Featuring Abbott Laboratories, Boston Scientific, and Medtronic
M2 - Mon Jun 30, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w9x4q9/global_coronary) has announced the addition of the "Global coronary Stent market through 2019" report to their offering. The global coronary stent market is expected to be over $13 billion by 2019 Increasing PCI procedures triggered by the rising prevalence of CAD, novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has remained stagnant for a few years. The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications. The stent market globally and in the developed nations is largely controlled by three players, Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume. This comprehensive, 465 page global strategic business report is authored by team of sector analysts who used rigorous primary and secondary research, robust analytical model to provide strategic insight and to forecast in for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies. Key Topics Covered: 1. Charts & Tables 2. Executive Summary 3. Market at a Glance 4. Introduction to Stents 5. Coronary Stents 6. Types of Stents 7. Approvals 8. Competitive Landscape 9. Clinical Studies 10. Coronary Stents - Market Drivers and Restrains 11. Overview: Market trends 12. Approvals Driving the Growth 13. Market Data 14. Company Profiles 15. Recent Events 16. Appendix Companies Mentioned - Abbott Vascular - Alvimedica Medical Technologies - Arterial Remodeling Technologies - Boston Scientific Corporation - Biosensors International - Biotronik SE & Co.kG - CID S.r.l. - Clearstream Technologies Ltd. - Disa Vascular (Pty) Ltd. - Elixir Medical Corporation - Endocor Gmbh - Essen Technology (Beijing) Co., Ltd - Hexacath - Iberhospitex S.A - InspireMD, Inc. - Japan Stent Technology Co., Ltd. - Kyoto Medical - Lepu Medical Technology Co., Ltd. - Medinol - Medtronic, Inc. - Meril Life Sciences Pvt. Ltd. - Micell Technologies, Inc. - MicroPort Scientific Corporation - Minvasys - OrbusNeich - Relisys Medical Devices Limited - Reva Medical, Inc. - Sahajanand Medical Technologies - Stentys - Terumo Medical Corporation For more information visit http://www.researchandmarkets.com/research/w9...l_coronary
InspireMD Receives European Regulatory Approval to Resume Manufacturing and Distribution of MGuard(TM) Prime EPS
PR Newswire - Mon Jun 23, 7:30AM CDT
InspireMD, Inc. ("InspireMD" or the "Company" (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it received European regulatory approval to resume the manufacturing of its MGuard Prime EPS stent with a modified stent securement process . The Company also received approval to modify and re-deploy existing MGuard Prime EPS stents that have been returned by clinical and commercial sites worldwide.
InspireMD to Present at the 9th Annual JMP Securities Healthcare Conference
PR Newswire - Wed Jun 18, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , today announced that its CEO, Alan Milinazzo, will be presenting at the 9th Annual JMP Securities Healthcare Conference at the Westin New York Grand Central in New York. The Company will present at 11:00 a.m. ET on Wednesday, June 25, 2014.
InspireMD Announces First Patient Enrolled Into New CGuard(TM) CARENET (CARotid Embolic protection study using microNET) Clinical Trial
PR Newswire - Wed Mar 19, 8:00AM CDT
InspireMD, Inc. ("InspireMD" or the "Company" (NYSE MKT: NSPR), a leader in embolic protection systems, today announced that it has successfully enrolled the first patient into the CARENET (CARotid Embolic protection study using microNET) multi-center European clinical trial for the new CGuard(TM) carotid embolic protection system.
InspireMD to Present at the 26th Annual ROTH Conference
PR Newswire - Thu Mar 06, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , today announced that its CEO, Alan Milinazzo, will be presenting at the 26th Annual ROTH Conference at the Ritz Carlton, Laguna Niguel in Dana Point, CA. The Company will present at 5:00 p.m. PT on Tuesday, March 11, 2014.
InspireMD to Present at the Cowen & Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , today announced that its CEO, Alan Milinazzo, will be presenting at the Cowen & Company 34th Annual Health Care Conference at The Boston Marriott Copley Place, in Boston. The Company will present at 9:20 a.m. EST on Wednesday, March 5, 2014.
InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013
PR Newswire - Wed Feb 26, 3:05PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems, today announced financial and operating results for the quarter and the six month period ended December 31, 2013.
InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014
PR Newswire - Tue Feb 18, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection stents, announced today that it will release its financial results for the six month period ended December 31, 2013 on February 26, 2014.
InspireMD Reports Successful Implantation of the New CGuard(TM) Carotid Embolic System with MicroNet(TM) Technology
PR Newswire - Wed Feb 05, 8:23AM CST
InspireMD, Inc. ("InspireMD" or the "Company" (NYSE MKT: NSPR), a leader in embolic protection systems, today announced that its new CGuard(TM) carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17th Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on February 1, 2014.
3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion by 2019
M2 - Mon Jan 27, 9:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rr9nj/3_catalysts_to) has announced the addition of the "3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion" report to their offering. The global coronary stent market is expected to be over $13 billion by 2019, despite the current downward trend in the US, the largest market, and declining selling prices globally. Increasing PCI (percutaneous coronary intervention) procedures triggered by the rising prevalence of CAD (coronary artery disease), novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has remained stagnant for a few years. The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications. The stent market globally and in the developed nations is largely controlled by three players - Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume. This comprehensive, 465 page global strategic business report is authored by a team of sector analysts who used rigorous primary and secondary research and robust analytical models to provide strategic insight and to forecast for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies. Data at global, continents, economic zones, and country level: - Market size of coronary stents in terms - value and volume (2005-2019) for BMS, DES and Bioabsorbables (Bioresorbable - BVS) - Market growth rates (2005-2019) - Average prices of various stents in all the covered geographies (2005-2019) - Number of PCI procedures - Analytical comparison between different continents and economic regions - Market dynamics - market trends, drivers, restrains, issues, competitive landscape - Detailed pipeline and clinical studies - Product approval status - major geographies - Industry consolidation, partnerships, product launches, approvals and recalls - Detailed company profiles of around 70 companies from different levels of value chain Key Topics Covered: 1. Charts & Tables 2. Executive Summary 3. Market at a Glance 4. Introduction to Stents 5. Coronary Stents 6. Types of Stents 7. Approvals 8. Competitive Landscape 9. Clinical Studies 10.Coronary Stents - Market Drivers and Restrains 11.Overview: Market trends 12.Approvals Driving the Growth 13. Market Data 14.Company Profiles 15.Recent Events 16.Appendix 17. Research Methodology 18. Disclaimer Companies Mentioned Include: - Abbott Vascular - Alvimedica Medical Technologies - Arterial Remodeling Technologies - Boston Scientific Corporation - Biosensors International - Biotronik SE & Co.kG - CID S.r.l. - Clearstream Technologies Ltd. - Disa Vascular (Pty) Ltd. - Elixir Medical Corporation - Endocor Gmbh - Essen Technology (Beijing) Co., Ltd - Hexacath - Iberhospitex S.A - InspireMD, Inc. - Japan Stent Technology Co., Ltd. - Kyoto Medical - Lepu Medical Technology Co., Ltd. - Medinol - Medtronic, Inc. - Meril Life Sciences Pvt. Ltd. - Micell Technologies, Inc. - MicroPort Scientific Corporation - Minvasys - OrbusNeich - Relisys Medical Devices Limited - Terumo Medical Corporation - Translumina - Tryton Medical - Vascular Concepts For more information visit http://www.researchandmarkets.com/research/3r...talysts_to
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 22, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
PR Newswire - Tue Sep 17, 3:05PM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection stents, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013.
InspireMD Announces Positive Results from CGuard(TM) CARENET Trial with 0% MACE reported at 30 Days
PR Newswire - Tue Sep 16, 3:10PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced positive results from the CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard(TM) EPS. This trial demonstrates that the MicroNet(TM) covered CGuard may offer important clinical benefits for patients undergoing carotid artery stenting (CAS). InspireMD to Present at the Aegis Healthcare and Technology Conference
PR Newswire - Wed Sep 03, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced that its Chief Financial Officer, Craig Shore, will be presenting at the Aegis Healthcare and Technology Conference at the Encore at Wynn Las Vegas. The Company will present on Friday, September 12, 2014 at 8:30 a.m. PT. InspireMD to Announce Results of CGuard(TM) CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies
PR Newswire - Mon Aug 11, 7:00AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced that Professor Joachim Schofer, MD, at the Hamburg University Cardiovascular Center, will present the results of the CARENET (CARotid Embolic protection using microNET) trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference, in Washington, D.C. on Tuesday September 16, 2014. InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014
PR Newswire - Wed Jul 23, 3:05PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced its financial and operating results for the second quarter, which ended June 30, 2014. InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2014 on Wednesday, July 23rd
PR Newswire - Thu Jul 17, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2014 on Wednesday, July 23rd. InspireMD Appoints Dr. James Barry as Chief Operating Officer
PR Newswire - Tue Jul 15, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems, today announced the appointment of James Barry, Ph.D. as Chief Operating Officer. Barry, who has more than two decades of experience in the medical device industry, will be based in the Company's Boston headquarters. InspireMD Announces Successful Completion of CGuard(TM) CARENET (CARotid Embolic protection study using microNET) Trial
PR Newswire - Tue Jul 08, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced that it has concluded enrollment in its CARENET clinical trial. The multi-specialty (Interventional Cardiologists, Interventional Radiologists and Vascular Surgeons) trial is assessing the peri-procedural safety and efficacy of CGuard systems in the treatment of carotid lesions. The acute procedural performance of the CGuard device was 100% successful for all of the 30 patients enrolled in the trial. InspireMD Selected for Inclusion in the Russell Microcap® Index
PR Newswire - Tue Jul 01, 7:30AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems, today announced that it has been selected to join the Russell Microcap Index, as of June 27, 2014. Global Coronary Stent Market through 2019 - Concise Analysis of the Projected $13 Billion Industry Featuring Abbott Laboratories, Boston Scientific, and Medtronic
M2 - Mon Jun 30, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w9x4q9/global_coronary) has announced the addition of the "Global coronary Stent market through 2019" report to their offering. The global coronary stent market is expected to be over $13 billion by 2019 Increasing PCI procedures triggered by the rising prevalence of CAD, novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has remained stagnant for a few years. The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications. The stent market globally and in the developed nations is largely controlled by three players, Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume. This comprehensive, 465 page global strategic business report is authored by team of sector analysts who used rigorous primary and secondary research, robust analytical model to provide strategic insight and to forecast in for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies. Key Topics Covered: 1. Charts & Tables 2. Executive Summary 3. Market at a Glance 4. Introduction to Stents 5. Coronary Stents 6. Types of Stents 7. Approvals 8. Competitive Landscape 9. Clinical Studies 10. Coronary Stents - Market Drivers and Restrains 11. Overview: Market trends 12. Approvals Driving the Growth 13. Market Data 14. Company Profiles 15. Recent Events 16. Appendix Companies Mentioned - Abbott Vascular - Alvimedica Medical Technologies - Arterial Remodeling Technologies - Boston Scientific Corporation - Biosensors International - Biotronik SE & Co.kG - CID S.r.l. - Clearstream Technologies Ltd. - Disa Vascular (Pty) Ltd. - Elixir Medical Corporation - Endocor Gmbh - Essen Technology (Beijing) Co., Ltd - Hexacath - Iberhospitex S.A - InspireMD, Inc. - Japan Stent Technology Co., Ltd. - Kyoto Medical - Lepu Medical Technology Co., Ltd. - Medinol - Medtronic, Inc. - Meril Life Sciences Pvt. Ltd. - Micell Technologies, Inc. - MicroPort Scientific Corporation - Minvasys - OrbusNeich - Relisys Medical Devices Limited - Reva Medical, Inc. - Sahajanand Medical Technologies - Stentys - Terumo Medical Corporation For more information visit http://www.researchandmarkets.com/research/w9...l_coronary
InspireMD Receives European Regulatory Approval to Resume Manufacturing and Distribution of MGuard(TM) Prime EPS
PR Newswire - Mon Jun 23, 7:30AM CDT
InspireMD, Inc. ("InspireMD" or the "Company"
(NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it received European regulatory approval to resume the manufacturing of its MGuard Prime EPS stent with a modified stent securement process . The Company also received approval to modify and re-deploy existing MGuard Prime EPS stents that have been returned by clinical and commercial sites worldwide. InspireMD to Present at the 9th Annual JMP Securities Healthcare Conference
PR Newswire - Wed Jun 18, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, today announced that its CEO, Alan Milinazzo, will be presenting at the 9th Annual JMP Securities Healthcare Conference at the Westin New York Grand Central in New York. The Company will present at 11:00 a.m. ET on Wednesday, June 25, 2014. InspireMD Announces First Patient Enrolled Into New CGuard(TM) CARENET (CARotid Embolic protection study using microNET) Clinical Trial
PR Newswire - Wed Mar 19, 8:00AM CDT
InspireMD, Inc. ("InspireMD" or the "Company"
(NYSE MKT: NSPR), a leader in embolic protection systems, today announced that it has successfully enrolled the first patient into the CARENET (CARotid Embolic protection study using microNET) multi-center European clinical trial for the new CGuard(TM) carotid embolic protection system. InspireMD to Present at the 26th Annual ROTH Conference
PR Newswire - Thu Mar 06, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, today announced that its CEO, Alan Milinazzo, will be presenting at the 26th Annual ROTH Conference at the Ritz Carlton, Laguna Niguel in Dana Point, CA. The Company will present at 5:00 p.m. PT on Tuesday, March 11, 2014. InspireMD to Present at the Cowen & Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, today announced that its CEO, Alan Milinazzo, will be presenting at the Cowen & Company 34th Annual Health Care Conference at The Boston Marriott Copley Place, in Boston. The Company will present at 9:20 a.m. EST on Wednesday, March 5, 2014. InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013
PR Newswire - Wed Feb 26, 3:05PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems, today announced financial and operating results for the quarter and the six month period ended December 31, 2013. InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014
PR Newswire - Tue Feb 18, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection stents, announced today that it will release its financial results for the six month period ended December 31, 2013 on February 26, 2014. InspireMD Reports Successful Implantation of the New CGuard(TM) Carotid Embolic System with MicroNet(TM) Technology
PR Newswire - Wed Feb 05, 8:23AM CST
InspireMD, Inc. ("InspireMD" or the "Company"
(NYSE MKT: NSPR), a leader in embolic protection systems, today announced that its new CGuard(TM) carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17th Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on February 1, 2014. 3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion by 2019
M2 - Mon Jan 27, 9:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rr9nj/3_catalysts_to) has announced the addition of the "3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion" report to their offering. The global coronary stent market is expected to be over $13 billion by 2019, despite the current downward trend in the US, the largest market, and declining selling prices globally. Increasing PCI (percutaneous coronary intervention) procedures triggered by the rising prevalence of CAD (coronary artery disease), novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has remained stagnant for a few years. The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications. The stent market globally and in the developed nations is largely controlled by three players - Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume. This comprehensive, 465 page global strategic business report is authored by a team of sector analysts who used rigorous primary and secondary research and robust analytical models to provide strategic insight and to forecast for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies. Data at global, continents, economic zones, and country level: - Market size of coronary stents in terms - value and volume (2005-2019) for BMS, DES and Bioabsorbables (Bioresorbable - BVS) - Market growth rates (2005-2019) - Average prices of various stents in all the covered geographies (2005-2019) - Number of PCI procedures - Analytical comparison between different continents and economic regions - Market dynamics - market trends, drivers, restrains, issues, competitive landscape - Detailed pipeline and clinical studies - Product approval status - major geographies - Industry consolidation, partnerships, product launches, approvals and recalls - Detailed company profiles of around 70 companies from different levels of value chain Key Topics Covered: 1. Charts & Tables 2. Executive Summary 3. Market at a Glance 4. Introduction to Stents 5. Coronary Stents 6. Types of Stents 7. Approvals 8. Competitive Landscape 9. Clinical Studies 10.Coronary Stents - Market Drivers and Restrains 11.Overview: Market trends 12.Approvals Driving the Growth 13. Market Data 14.Company Profiles 15.Recent Events 16.Appendix 17. Research Methodology 18. Disclaimer Companies Mentioned Include: - Abbott Vascular - Alvimedica Medical Technologies - Arterial Remodeling Technologies - Boston Scientific Corporation - Biosensors International - Biotronik SE & Co.kG - CID S.r.l. - Clearstream Technologies Ltd. - Disa Vascular (Pty) Ltd. - Elixir Medical Corporation - Endocor Gmbh - Essen Technology (Beijing) Co., Ltd - Hexacath - Iberhospitex S.A - InspireMD, Inc. - Japan Stent Technology Co., Ltd. - Kyoto Medical - Lepu Medical Technology Co., Ltd. - Medinol - Medtronic, Inc. - Meril Life Sciences Pvt. Ltd. - Micell Technologies, Inc. - MicroPort Scientific Corporation - Minvasys - OrbusNeich - Relisys Medical Devices Limited - Terumo Medical Corporation - Translumina - Tryton Medical - Vascular Concepts For more information visit http://www.researchandmarkets.com/research/3r...talysts_to
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 22, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
PR Newswire - Tue Sep 17, 3:05PM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection stents, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013. 
